Correlation Between Ikena Oncology and Cyclacel Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Ikena Oncology and Cyclacel Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ikena Oncology and Cyclacel Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Ikena Oncology and Cyclacel Pharmaceuticals, you can compare the effects of market volatilities on Ikena Oncology and Cyclacel Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ikena Oncology with a short position of Cyclacel Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ikena Oncology and Cyclacel Pharmaceuticals.

Diversification Opportunities for Ikena Oncology and Cyclacel Pharmaceuticals

0.63

Correlation Coefficient

Ikena Oncology  Cyclacel Pharmaceuticals

Poor diversification

The 3 months correlation between Ikena and Cyclacel is 0.63. Overlapping area represents the amount of risk that can be diversified away by holding Ikena Oncology and Cyclacel Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cyclacel Pharmaceuticals and Ikena Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ikena Oncology are associated (or correlated) with Cyclacel Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cyclacel Pharmaceuticals has no effect on the direction of Ikena Oncology i.e., Ikena Oncology and Cyclacel Pharmaceuticals go up and down completely randomly.

Pair Corralation between Ikena Oncology and Cyclacel Pharmaceuticals

Given the investment horizon of 90 days Ikena Oncology is expected to under-perform the Cyclacel Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Ikena Oncology is 2.48 times less risky than Cyclacel Pharmaceuticals. The stock trades about -0.12 of its potential returns per unit of risk. The Cyclacel Pharmaceuticals is currently generating about -0.04 of returns per unit of risk over similar time horizon. If you would invest  37.00  in Cyclacel Pharmaceuticals on December 29, 2024 and sell it today you would lose (7.00) from holding Cyclacel Pharmaceuticals or give up 18.92% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Ikena Oncology  vs.  Cyclacel Pharmaceuticals

Ikena Oncology

Risk-Adjusted Performance

Very Weak

Over the last 90 days Ikena Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Cyclacel Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Cyclacel Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's fundamental indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.

Pair Trading with Ikena Oncology and Cyclacel Pharmaceuticals

The main advantage of trading using opposite Ikena Oncology and Cyclacel Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ikena Oncology position performs unexpectedly, Cyclacel Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclacel Pharmaceuticals will offset losses from the drop in Cyclacel Pharmaceuticals' long position.

The idea behind Ikena Oncology and Cyclacel Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.